CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.1186/s12933-024-02180-8
dc.identifier.other
WOS:001334087200001
dc.description.volume
dc.description.issue
Publisher
BMC
DOI
10.1186/s12933-024-02180-8
Abstract
Description
Keywords
Cardiovascular disease , Chronic kidney disease , CGM , Diabetes , Finerenone , GLP\\-1 RA , Guidelines , Heart failure , MASLD , NAFLD , Obesity , SGLT2 inhibitor , Teplizumab